Last reviewed · How we verify

NCT06923566

Targeted Muscle Reinnervation in the Hand for the Managment of Symptomatic Neuroma Following Digit and Hand Amputations

Completed NA Last updated 11 April 2025
What this trial tests

NA trial testing Targeted muscle reinnervation in Targeted Muscle Reinervation in 17 participants. Completed in 2 September 2023.

Timeline
20 August 2021
Primary endpoint
30 July 2023
2 September 2023

Quick facts

Lead sponsorAin Shams University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment17
Start date20 August 2021
Primary completion30 July 2023
Estimated completion2 September 2023
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Ain Shams University

Who can join

18 and older, any sex, with Targeted Muscle Reinervation or Digital Amputation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Neuromas are a common complication after digital and hand amputations, resulting in significant pain, discomfort, and functional impairment. Various management methods are available, including surgical excision, nerve blocks, and nerve stump protectors, but these treatments may have limited success rates and potential complications. Targeted muscle reinnervation (TMR) is a promising technique that involves surgically rerouting a severed nerve into a nearby muscle, which can prevent the formation of neuromas and provide improved muscle function

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Ain Shams University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06923566.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing